Cyclosporine 0.05% Ophthalmic Emulsion for Dry Eye in Korea: A Prospective, Multicenter, Open-Label, Surveillance Study
1
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Purpose: To assess the effectiveness and tolerability of cyclosporine ophthalmic emulsion (CsA) 0.05% in patients with moderate to severe dry eye disease in Korea. Methods: This was a prospective, multicenter, open-label, surveillance study of 392 Korean patients with moderate to severe dry eye disease who were treated with CsA 0.05% for three months. An assessment of effectiveness was performed at baseline, and after 1, 2, and 3 months. The primary effectiveness outcomes were changes in ocular symptoms and Schirmer score. The secondary effectiveness outcomes were a change in conjunctival staining, use of artificial tears, global evaluation of treatment, and patient satisfaction. The primary safety outcome was the incidence and nature of adverse events. Results: A total of 362 patients completed the study. After three months, all ocular symptom scores were significantly reduced compared to the baseline values, while the Schirmer scores were significantly increased relative to baseline (p < 0.0001). After three months, there were significant reductions from baseline in conjunctival staining (p < 0.01) and use of artificial tears (p < 0.0001). According to clinicians’ global evaluations, most patients (>50%) experienced at least a 25% to 50% improvement in symptoms from baseline at each follow-up visit. The majority of patients (72.0%) were satisfied with the treatment results, and 57.2% reported having no or mild symptoms after treatment. The most common adverse events were ocular pain (11.0%). Conclusions: Our findings indicate that CsA 0.05% is an effective and tolerable treatment for dry eye disease in Korean clinical practice.
Abstract
Purpose: To assess the effectiveness and tolerability of cyclosporine ophthalmic emulsion (CsA) 0.05% in patients with moderate to severe dry eye disease in Korea. Methods: This was a prospective, multicenter, open-label, surveillance study of 392 Korean patients with moderate to severe dry eye disease who were treated with CsA 0.05% for three months. An assessment of effectiveness was performed at baseline, and after 1, 2, and 3 months. The primary effectiveness outcomes were changes in ocular symptoms and Schirmer score. The secondary effectiveness outcomes were a change in conjunctival staining, use of artificial tears, global evaluation of treatment, and patient satisfaction. The primary safety outcome was the incidence and nature of adverse events. Results: A total of 362 patients completed the study. After three months, all ocular symptom scores were significantly reduced compared to the baseline values, while the Schirmer scores were significantly increased relative to baseline (p < 0.0001). After three months, there were significant reductions from baseline in conjunctival staining (p < 0.01) and use of artificial tears (p < 0.0001). According to clinicians’ global evaluations, most patients (>50%) experienced at least a 25% to 50% improvement in symptoms from baseline at each follow-up visit. The majority of patients (72.0%) were satisfied with the treatment results, and 57.2% reported having no or mild symptoms after treatment. The most common adverse events were ocular pain (11.0%). Conclusions: Our findings indicate that CsA 0.05% is an effective and tolerable treatment for dry eye disease in Korean clinical practice.
참고문헌 (30)
- O'Brien PD, "Dry eye:diagnosis and current treatment strategies", Curr Allergy Asthma Rep, 4, pp.314~319 (2004)
- Hikichi T, "Prevalence of dry eye in Japanese eye centers", Graefes Arch Clin Exp Ophthalmol, 233, pp.555~558 (1995)
- Jamaliah R, "Prevalence of dry eye in University Malaya Medical Centre", Med J Malaysia, 57, pp.390~397 (2002)
- Lekhanont K, "Prevalence of dry eye in Bangkok,Thailand", Cornea, 25, pp.1162~1167 (2006)
- Shimmura S, "Results of a populationbased questionnaire on the symptoms and lifestyles associated with dry eye", Cornea, 18, pp.408~411 (1999)
- Lee AJ, "Prevalence and risk factors associated with dry eye symptoms:a population based study in Indonesia", Br J Ophthalmol, 86, pp.1347~1351 (2002)
- Lin PY, "Association between symptoms and signs of dry eye among an elderly Chinese population in Taiwan:the Shihpai Eye Study", Invest Ophthalmol Vis Sci, 46, pp.1593~1598 (2005)
- Lu P, "Dry eye syndrome in elderly Tibetans at high altitude:a population-based study in China", Cornea, 27, pp.545~551 (2008)
- Jie Y, "Prevalence of dry eye among adult Chinese in the Beijing Eye Study", Eye(Lond), 23, pp.688~693 (2009)
- Doughty MJ, "A patient questionnaire approach to estimating the prevalence of dry eye symptoms in patients presenting to optometric practices across Canada", Optom Vis Sci, 74, pp.624~631 (1997)
- McCarty CA, "The epidemiology of dry eye in Melbourne,Australia", Ophthalmology, 105, pp.1114~1119 (1998)
- Moss SE, "Prevalence of and risk factors for dry eye syndrome", Arch Ophthalmol, 118, pp.1264~1268 (2000)
- "The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop", Ocul Surf, 2007(5), pp.93~107 (2007)
- Reddy P, "The economic burden of dry eye:a conceptual framework and preliminary assessment", Cornea, 23, pp.751~761 (2004)
- Pflugfelder SC, "Prevalence, burden, and pharmacoeconomics of dry eye disease", Am J Manag Care, 14(3 Suppl), pp.S102~S106 (2008)
- Miljanovic B, "Impact of dry eye syndrome on vision-related quality of life", Am J Ophthalmol, 143, pp.409~415 (2007)
- "The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop", Ocul Surf, 2007(5), pp.75~92 (2007)
- Doughty MJ, "Efficacy of different dry eye treatments with artificial tears or ocular lubricants:a systematic review", Ophthalmic Physiol Opt, 29, pp.573~583 (2009)
- Gayton JL, "Etiology,prevalence,and treatment of dry eye disease", Clin Ophthalmol, 3, pp.405~412 (2009)
- "Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop", Ocul Surf, 2007(5), pp.163~178 (2007)
- Sall K, "Two multicenter,randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease.CsA Phase 3 Study Group", Ophthalmology, 107, pp.631~639 (2000)
- Stevenson D, "Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease:a dose-ranging,randomized trial.The Cyclosporin A Phase 2 Study Group", Ophthalmology, 107, pp.967~974 (2000)
- Perry HD, "Evaluation of topical cyclosporine for the treatment of dry eye disease", Arch Ophthalmol, 126, pp.1046~1050 (2008)
- Jun Woong Moon, "Short Term Effects of Topical Cyclosporine and Viscoelastic on the Ocular Surfaces in Patients with Dry Eye", Korean Journal of Ophthalmology, 21(4), pp.189~194 (2007), 대한안과학회
- Kim EC, "A Comparison of Vitamin A and Cyclosporine A 0.05% Eye Drops for Treatment of Dry Eye Syndrome", AMERICAN JOURNAL OF OPHTHALMOLOGY, 147(2), pp.206~213, ELSEVIER SCIENCE INC
- 변용수, "안구건조증 환자에서 사이클로스포린 0.05퍼센트 점안액의 임상효과", 대한안과학회지, 49(10), pp.1583~1588 (2008), 대한안과학회
- 이종수, "경도의 안구 건조증에서 레스타시스®의 임상 효과", 대한안과학회지, 50(10), pp.1489~1494 (2009), 대한안과학회
- Hanson J, "Schirmer test of lacrimation.Its clinical importance", Arch Otolaryngol, 101, pp.293~295 (1975)
- Stonecipher K, "The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca", Curr Med Res Opin, 21, pp.1057~1063 (2005)
- Trattler W, "Self-reported compliance with topical cyclosporine emulsion 0.05% and onset of the effects of increased tear production as assessed through patient surveys", Clin Ther, 28, pp.1848~1856 (2006)